Jun. 23 at 11:08 PM
$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by
$VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping
$470 million in cash (or
$8/share) and another
$2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy.
....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.